ITGA3-Targeting Antibodies for Cancer Cell Internalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapeutic agents, suffer from cytotoxicity to both tumor and normal cells, limiting dose effectiveness and causing side effects, while antibody-drug conjugates face challenges in identifying antibodies with high internalization ability for targeted cancer cell delivery.
Innovation Solution
Development of antibodies specific to cancer stem cell or cancer cell membrane proteins, comprising specific VH and VL CDR sequences, which are used in antibody-drug conjugates to target and internalize into cancer cells, and can be part of chimeric antigen receptors for immune cells, diagnostic compositions, and cancer diagnostic kits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic agents are used to treat cancer, then the full therapeutic effect cannot be achieved, but side effects occur due to cytotoxicity to normal cells
Solution Approach 1:
The invention segments the therapeutic action by separating the cytotoxic drug from normal cells through antibody-guided targeting. The antibody-drug conjugate delivers the cytotoxic agent specifically to cancer cells expressing the target antigen, segmenting the harmful effect from healthy tissues while concentrating the therapeutic action where needed.
Solution Approach 2:
The antibody serves as an intermediary molecule that bridges the cytotoxic drug and the cancer cell. It binds specifically to the target antigen on cancer cells and internalizes the conjugate, mediating the delivery of the cytotoxic agent selectively to malignant cells while sparing normal cells that lack the target antigen.
2Reliability
If sufficient doses of chemotherapeutic agents are administered to achieve full therapeutic effect, then treatment efficacy improves, but cytotoxicity to normal cells increases
Solution Approach 1:
The invention applies local quality by concentrating the cytotoxic agent's effect specifically at the cancer cell location through antibody targeting. The high local concentration of the drug is achieved at the tumor site via antigen-specific binding and internalization, while normal tissues receive minimal exposure, allowing sufficient dosing without proportional increase in systemic cytotoxicity.
3Reliability
If antibodies with high internalization ability are used in ADCs to improve cancer cell delivery, then drug accumulation in cancer cells increases, but it is difficult to identify suitable antibodies from molecular structure or binding properties
Solution Approach 1:
The invention changes the selection parameter from relying on binding affinity or molecular structure characteristics to using a cell-based internalization assay. This parameter change enables direct measurement of the critical internalization function, allowing identification of antibodies with high internalization ability regardless of their binding properties or structural features.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies effectively deliver cytotoxic agents to cancer cells, reducing side effects by specifically targeting and internalizing into cancer cells, enhancing treatment efficacy and providing diagnostic and therapeutic options.
Implementation Method 1
antibodies have high blood stability and bind specifically to target antigens
Implementation Method 2
internalize the antigen into the cell through that binding
Data Source
Figure 1~3B
Figure 4a~4b
Figure 4c~4d
AI summary
The present invention relates to a cancer cell-specific antibody and its use. According to one aspect, an antibody specific to a membrane protein of a cancer stem cell or a cancer cell exhibits strong affinity for ITGA3 or VLA3 and excellent cell internalization, and thus can be usefully used in research on diagnosis, treatment, or development of therapeutic agents for various cancers in the form of unconjugated antibodies, antibody-drug conjugates (ADCs), and other antibody complexes based on the antibody.